Pfizer Inc. (NYSE:PFE) Shares Sold by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV lowered its stake in Pfizer Inc. (NYSE:PFE) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 740,180 shares of the biopharmaceutical company’s stock after selling 189,942 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Pfizer were worth $19,637,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PFE. Virtu Financial LLC bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $1,499,000. World Investment Advisors LLC boosted its holdings in Pfizer by 61.1% during the third quarter. World Investment Advisors LLC now owns 127,265 shares of the biopharmaceutical company’s stock worth $3,683,000 after buying an additional 48,281 shares in the last quarter. Tidal Investments LLC boosted its holdings in Pfizer by 13.1% during the third quarter. Tidal Investments LLC now owns 190,628 shares of the biopharmaceutical company’s stock worth $5,517,000 after buying an additional 22,068 shares in the last quarter. Trust Co of the South boosted its holdings in Pfizer by 6.1% during the fourth quarter. Trust Co of the South now owns 28,945 shares of the biopharmaceutical company’s stock worth $768,000 after buying an additional 1,667 shares in the last quarter. Finally, Versant Capital Management Inc boosted its holdings in Pfizer by 53.3% during the fourth quarter. Versant Capital Management Inc now owns 6,799 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 2,365 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.64.

Pfizer Stock Down 2.1 %

PFE stock opened at $23.91 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $135.59 billion, a price-to-earnings ratio of 16.96, a PEG ratio of 0.64 and a beta of 0.67. The company has a 50 day moving average of $24.39 and a two-hundred day moving average of $25.82.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The company’s revenue was down 7.8% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.19%. Pfizer’s payout ratio is 124.64%.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.